Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Precision medicine in premature ovarian insufficiency: a focus on the precision therapeutic strategies for mesenchymal stem cells

Wang R., Liu F., Liao Q., Wu J., Wang L., Li K.

Narrative Review on Hip, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40671085
PMCID
PMC12269181
DOI
10.1186/s13287-025-04512-1

Abstract (original English)

Premature ovarian insufficiency (POI) is one of the most common disorders that reduces fertility and the quality of life in young women. And mesenchymal stem cells (MSCs) have gradually been regarded as a promising therapeutic approach for POI for their potential in remodeling impaired ovarian function. However, specific details regarding the application of MSCs in POI treatment remain unclear. Key issues include the selection of appropriate MSCs sources, the optimization of culture conditions, and the determination of optimal transplantation protocols (encompassing dosage, administration route, and timing), all of which pose significant barriers to clinical translation of MSCs. Here, this paper systematically reviews the researches on MSCs-based POI therapy from mechanism to clinical application, with a focus on the key therapeutic details. Additionally, it highlights the application potential of fetal adnexa sources, in site transplantation, hypoxic environment and three-dimensional cultivation strategy for MSCs and provides an integrated analysis of MSCs' dose efficacy inverted U-shaped relationship. Given the crucial role of MSCs' targeting ability and therapeutic duration in precision medicine, this paper further explores the challenges, existing strategies, and future development directions of MSCs in this field, intending to provide a comprehensive reference for future r

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansMesenchymal Stem Cell TransplantationFemalePrimary Ovarian InsufficiencyPrecision Medicine

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research